drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00283 | DB01202 | 701 | 1,435 | [
"DDInter395",
"DDInter1046"
] | Clemastine | Levetiracetam | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).[L8606,L8600,L8615] Levetiracetam poss... | Moderate | 1 | [
[
[
701,
24,
1435
]
],
[
[
701,
18,
4930
],
[
4930,
57,
1435
]
],
[
[
701,
21,
28769
],
[
28769,
60,
1435
]
],
[
[
701,
24,
475
],
[
475,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levetiracetam"
]
],
[
[
"Clemastine",
"{u} (Compound) downregulates {v} (Gene)",
"DLD"
],
[
"DLD",
"{u} (Gene) is downregulated by {v}... | Clemastine (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Levetiracetam (Compound)
Clemastine (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Levetiracetam (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when ... |
DB00047 | DB06595 | 176 | 1,491 | [
"DDInter932",
"DDInter1214"
] | Insulin glargine | Midostaurin | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
176,
24,
1491
]
],
[
[
176,
24,
1247
],
[
1247,
23,
1491
]
],
[
[
176,
24,
761
],
[
761,
24,
1491
]
],
[
[
176,
25,
956
],
[
956,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazo... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB01240 | DB14006 | 885 | 972 | [
"DDInter657",
"DDInter370"
] | Epoprostenol | Choline salicylate | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Choline salicylate is an anti-inflammatory pain reliever agent that is related to aspirin. It is used to decrease swelling and to treat mild-moderate pain. It is used to treat arthritis in both children and adults. This medicine can also be used for fever . Choline Salicylate is the choline salt of salicylic acid, used... | Moderate | 1 | [
[
[
885,
24,
972
]
],
[
[
885,
64,
553
],
[
553,
24,
972
]
],
[
[
885,
63,
291
],
[
291,
24,
972
]
],
[
[
885,
40,
1061
],
[
1061,
2... | [
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Choline salicylate"
]
],
[
[
"Epoprostenol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fondaparinux"
],
[
... | Epoprostenol may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate
Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Argatroban and Argat... |
DB01083 | DB01278 | 1,142 | 1,021 | [
"DDInter1348",
"DDInter1506"
] | Orlistat | Pramlintide | The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical inter... | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
1142,
24,
1021
]
],
[
[
1142,
63,
1560
],
[
1560,
24,
1021
]
],
[
[
1142,
24,
34
],
[
34,
63,
1021
]
],
[
[
1142,
24,
1327
],
[
1327,
... | [
[
[
"Orlistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Orlistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
... | Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir and Fo... |
DB00792 | DB04908 | 832 | 1,671 | [
"DDInter1878",
"DDInter741"
] | Tripelennamine | Flibanserin | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Moderate | 1 | [
[
[
832,
24,
1671
]
],
[
[
832,
63,
1594
],
[
1594,
24,
1671
]
],
[
[
832,
24,
407
],
[
407,
63,
1671
]
],
[
[
832,
24,
1532
],
[
1532,
... | [
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],... | Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Op... |
DB00674 | DB11986 | 1,516 | 484 | [
"DDInter802",
"DDInter648"
] | Galantamine | Entrectinib | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sour... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
1516,
24,
484
]
],
[
[
1516,
24,
112
],
[
112,
23,
484
]
],
[
[
1516,
24,
774
],
[
774,
24,
484
]
],
[
[
1516,
63,
322
],
[
322,
... | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Degarelix and ... |
DB12147 | DB14520 | 241 | 1,229 | [
"DDInter661",
"DDInter1785"
] | Erdafitinib | Tetraferric tricitrate decahydrate | In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations... | Tetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease. Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014. | Major | 2 | [
[
[
241,
25,
1229
]
],
[
[
241,
64,
460
],
[
460,
63,
955
],
[
955,
23,
1229
]
],
[
[
241,
64,
460
],
[
460,
62,
954
],
[
954,
24,
... | [
[
[
"Erdafitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Erdafitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Magnesium carbonate"
],
... | Erdafitinib may lead to a major life threatening interaction when taken with Magnesium carbonate and Magnesium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil may cause a minor interaction that can limit clinical effects when take... |
DB06603 | DB10276 | 39 | 1,624 | [
"DDInter1387",
"DDInter1623"
] | Panobinostat | Rotavirus vaccine | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Major | 2 | [
[
[
39,
25,
1624
]
],
[
[
39,
63,
770
],
[
770,
25,
1624
]
],
[
[
39,
64,
51
],
[
51,
25,
1624
]
],
[
[
39,
25,
375
],
[
375,
25,
... | [
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
... | Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Rotavirus vaccine
Panobinostat may lead to a major life threatening interaction when taken with Daunorubicin and Daunorubicin may lead... |
DB00322 | DB00544 | 141 | 970 | [
"DDInter742",
"DDInter757"
] | Floxuridine | Fluorouracil | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Moderate | 1 | [
[
[
141,
24,
970
]
],
[
[
141,
5,
11616
],
[
11616,
44,
970
]
],
[
[
141,
6,
8569
],
[
8569,
45,
970
]
],
[
[
141,
7,
2969
],
[
2969,
... | [
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluorouracil"
]
],
[
[
"Floxuridine",
"{u} (Compound) treats {v} (Disease)",
"stomach cancer"
],
[
"stomach cancer",
"{u} (Disease) i... | Floxuridine (Compound) treats stomach cancer (Disease) and stomach cancer (Disease) is treated by Fluorouracil (Compound)
Floxuridine (Compound) binds TYMS (Gene) and TYMS (Gene) is bound by Fluorouracil (Compound)
Floxuridine (Compound) upregulates CDKN1A (Gene) and CDKN1A (Gene) is upregulated by Fluorouracil (Compou... |
DB00188 | DB00615 | 168 | 690 | [
"DDInter222",
"DDInter1589"
] | Bortezomib | Rifabutin | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Major | 2 | [
[
[
168,
25,
690
]
],
[
[
168,
25,
463
],
[
463,
1,
690
]
],
[
[
168,
6,
8374
],
[
8374,
45,
690
]
],
[
[
168,
7,
14278
],
[
14278,
... | [
[
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rifabutin"
]
],
[
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} (C... | Bortezomib may lead to a major life threatening interaction when taken with Rifampicin and Rifampicin (Compound) resembles Rifabutin (Compound)
Bortezomib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifabutin (Compound)
Bortezomib (Compound) upregulates PHKG2 (Gene) and PHKG2 (Gene) is upregulated by R... |
DB01033 | DB06168 | 328 | 1,531 | [
"DDInter1156",
"DDInter281"
] | Mercaptopurine | Canakinumab | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
328,
24,
1531
]
],
[
[
328,
63,
1461
],
[
1461,
23,
1531
]
],
[
[
328,
63,
377
],
[
377,
24,
1531
]
],
[
[
328,
24,
1270
],
[
1270,
... | [
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
... | Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Canakinumab
Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mi... |
DB00486 | DB01589 | 1,614 | 481 | [
"DDInter1253",
"DDInter1552"
] | Nabilone | Quazepam | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors a... | Moderate | 1 | [
[
[
1614,
24,
481
]
],
[
[
1614,
24,
1216
],
[
1216,
1,
481
]
],
[
[
1614,
63,
523
],
[
523,
1,
481
]
],
[
[
1614,
63,
905
],
[
905,
... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
],
[
"F... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Quazepam (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam and Alprazolam (Compound) resembles Quazepam (Compound)
Nabilone... |
DB08864 | DB08899 | 786 | 129 | [
"DDInter1595",
"DDInter649"
] | Rilpivirine | Enzalutamide | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Major | 2 | [
[
[
786,
25,
129
]
],
[
[
786,
63,
918
],
[
918,
1,
129
]
],
[
[
786,
6,
8374
],
[
8374,
45,
129
]
],
[
[
786,
21,
28921
],
[
28921,
... | [
[
[
"Rilpivirine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Rilpivirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
[
"Bica... | Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Rilpivirine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Rilpivirine (Compound) causes Dizziness (Side Effect) an... |
DB00261 | DB00500 | 702 | 24 | [
"DDInter93",
"DDInter1831"
] | Anagrelide | Tolmetin | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Moderate | 1 | [
[
[
702,
24,
24
]
],
[
[
702,
24,
558
],
[
558,
1,
24
]
],
[
[
702,
24,
831
],
[
831,
40,
24
]
],
[
[
702,
18,
16896
],
[
16896,
57,... | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolmetin"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zolpidem"
],
[
... | Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Zolpidem and Zolpidem (Compound) resembles Tolmetin (Compound)
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin (Compound) resembles Tolmetin (Compound)
Anag... |
DB01068 | DB06282 | 1,565 | 516 | [
"DDInter411",
"DDInter1053"
] | Clonazepam | Levocetirizine | A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechan... | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
1565,
24,
516
]
],
[
[
1565,
62,
1031
],
[
1031,
23,
516
]
],
[
[
1565,
24,
1074
],
[
1074,
63,
516
]
],
[
[
1565,
63,
701
],
[
701,
... | [
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Clonazepam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Theophylline"
],
... | Clonazepam may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Levocetirizine
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 and ... |
DB00081 | DB00472 | 273 | 758 | [
"DDInter1838",
"DDInter758"
] | Tositumomab | Fluoxetine | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Moderate | 1 | [
[
[
273,
24,
758
]
],
[
[
273,
24,
109
],
[
109,
40,
758
]
],
[
[
273,
64,
20
],
[
20,
24,
758
]
],
[
[
273,
25,
936
],
[
936,
63,
... | [
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
],
[
... | Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine (Compound) resembles Fluoxetine (Compound)
Tositumomab may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerba... |
DB12141 | DB15982 | 971 | 1,339 | [
"DDInter817",
"DDInter193"
] | Gilteritinib | Berotralstat | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat ... | Moderate | 1 | [
[
[
971,
24,
1339
]
],
[
[
971,
64,
1101
],
[
1101,
23,
1339
]
],
[
[
971,
24,
283
],
[
283,
23,
1339
]
],
[
[
971,
63,
761
],
[
761,
... | [
[
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Berotralstat"
]
],
[
[
"Gilteritinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexa... | Gilteritinib may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may ca... |
DB01136 | DB01362 | 772 | 497 | [
"DDInter305",
"DDInter960"
] | Carvedilol | Iohexol | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Moderate | 1 | [
[
[
772,
24,
497
]
],
[
[
772,
24,
258
],
[
258,
40,
497
]
],
[
[
772,
21,
28681
],
[
28681,
60,
497
]
],
[
[
772,
24,
1013
],
[
1013,
... | [
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
]
],
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodixanol"
],
[
... | Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Iodixanol and Iodixanol (Compound) resembles Iohexol (Compound)
Carvedilol (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Carvedilol may cause a moderate intera... |
DB11986 | DB14881 | 484 | 180 | [
"DDInter648",
"DDInter1329"
] | Entrectinib | Oliceridine | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
484,
24,
180
]
],
[
[
484,
62,
112
],
[
112,
23,
180
]
],
[
[
484,
63,
401
],
[
401,
24,
180
]
],
[
[
484,
24,
1476
],
[
1476,
2... | [
[
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Entrectinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Entrectinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and... |
DB05273 | DB06176 | 507 | 1,342 | [
"DDInter1638",
"DDInter1616"
] | Samarium (153Sm) lexidronam | Romidepsin | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium ... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Major | 2 | [
[
[
507,
25,
1342
]
],
[
[
507,
25,
1491
],
[
1491,
63,
1342
]
],
[
[
507,
64,
51
],
[
51,
24,
1342
]
],
[
[
507,
63,
789
],
[
789,
... | [
[
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
],
[
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
],
... | Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Daunorubicin an... |
DB00405 | DB00425 | 128 | 558 | [
"DDInter517",
"DDInter1970"
] | Dexbrompheniramine | Zolpidem | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of s... | Moderate | 1 | [
[
[
128,
24,
558
]
],
[
[
128,
24,
407
],
[
407,
63,
558
]
],
[
[
128,
74,
1594
],
[
1594,
24,
558
]
],
[
[
128,
63,
1242
],
[
1242,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zolpidem"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Zolpidem
Dexbrompheniramine (Compound) resembles Doxylamine (Compound) and Dexbrompheniramine may cause a moderate interactio... |
DB08864 | DB09154 | 786 | 1,475 | [
"DDInter1595",
"DDInter1686"
] | Rilpivirine | Sodium citrate | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Moderate | 1 | [
[
[
786,
24,
1475
]
],
[
[
786,
63,
355
],
[
355,
23,
1475
]
],
[
[
786,
63,
594
],
[
594,
24,
1475
]
],
[
[
786,
74,
1250
],
[
1250,
... | [
[
[
"Rilpivirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium citrate"
]
],
[
[
"Rilpivirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
... | Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosut... |
DB01234 | DB11718 | 1,220 | 927 | [
"DDInter513",
"DDInter640"
] | Dexamethasone | Encorafenib | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
1220,
25,
927
]
],
[
[
1220,
24,
720
],
[
720,
24,
927
]
],
[
[
1220,
23,
659
],
[
659,
24,
927
]
],
[
[
1220,
63,
536
],
[
536,
... | [
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
],
[
"Mi... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol and... |
DB00514 | DB01224 | 506 | 623 | [
"DDInter527",
"DDInter1553"
] | Dextromethorphan | Quetiapine | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Moderate | 1 | [
[
[
506,
24,
623
]
],
[
[
506,
25,
827
],
[
827,
1,
623
]
],
[
[
506,
63,
695
],
[
695,
1,
623
]
],
[
[
506,
24,
252
],
[
252,
1,
... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
]
],
[
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trazodone"
],
[
... | Dextromethorphan may lead to a major life threatening interaction when taken with Trazodone and Trazodone (Compound) resembles Quetiapine (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) resembles Quetiapine (Compound)
Dextrom... |
DB00572 | DB00835 | 85 | 100 | [
"DDInter136",
"DDInter245"
] | Atropine | Brompheniramine | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
85,
24,
100
]
],
[
[
85,
24,
832
],
[
832,
24,
100
]
],
[
[
85,
63,
508
],
[
508,
24,
100
]
],
[
[
85,
24,
211
],
[
211,
63,
... | [
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
... | Atropine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Promazine an... |
DB01246 | DB12161 | 820 | 730 | [
"DDInter45",
"DDInter512"
] | Alimemazine | Deutetrabenazine | A phenothiazine derivative that is used as an antipruritic. | Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives ... | Major | 2 | [
[
[
820,
25,
730
]
],
[
[
820,
62,
112
],
[
112,
23,
730
]
],
[
[
820,
63,
322
],
[
322,
24,
730
]
],
[
[
820,
24,
971
],
[
971,
24,... | [
[
[
"Alimemazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"M... | Alimemazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Deutetrabenazine
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin ... |
DB00332 | DB00726 | 1,089 | 1,164 | [
"DDInter970",
"DDInter1876"
] | Ipratropium | Trimipramine | Ipratropium is a quaternary ammonium derivative of [atropine] that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its... | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Moderate | 1 | [
[
[
1089,
24,
1164
]
],
[
[
1089,
24,
1237
],
[
1237,
40,
1164
]
],
[
[
1089,
63,
21
],
[
21,
40,
1164
]
],
[
[
1089,
6,
8374
],
[
8374,
... | [
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
],
... | Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Trimipramine (Compound)
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Amitriptyline and Amitriptyline (Compound) resembles Trimipra... |
DB00619 | DB13874 | 1,419 | 1,501 | [
"DDInter909",
"DDInter639"
] | Imatinib | Enasidenib | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345]. Patients eligible ... | Moderate | 1 | [
[
[
1419,
24,
1501
]
],
[
[
1419,
63,
663
],
[
663,
24,
1501
]
],
[
[
1419,
24,
1619
],
[
1619,
24,
1501
]
],
[
[
1419,
24,
829
],
[
829,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enasidenib"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucapar... |
DB00377 | DB01209 | 1,494 | 1,359 | [
"DDInter1382",
"DDInter531"
] | Palonosetron | Dezocine | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Dezocine is a partial opiate drug and is used for pain management. Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea. | Moderate | 1 | [
[
[
1494,
24,
1359
]
],
[
[
1494,
25,
234
],
[
234,
1,
1359
]
],
[
[
1494,
25,
1264
],
[
1264,
24,
1359
]
],
[
[
1494,
24,
1662
],
[
1662,... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentazocine"
],
[
"Pentazo... | Palonosetron may lead to a major life threatening interaction when taken with Pentazocine and Pentazocine (Compound) resembles Dezocine (Compound)
Palonosetron may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00242 | DB01222 | 1,064 | 617 | [
"DDInter392",
"DDInter246"
] | Cladribine | Budesonide | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Major | 2 | [
[
[
1064,
25,
617
]
],
[
[
1064,
64,
1351
],
[
1351,
1,
617
]
],
[
[
1064,
25,
251
],
[
251,
1,
617
]
],
[
[
1064,
7,
7669
],
[
7669,
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Flunisolide"
],
[
"Flunisolide",
"{u}... | Cladribine may lead to a major life threatening interaction when taken with Flunisolide and Flunisolide (Compound) resembles Budesonide (Compound)
Cladribine may lead to a major life threatening interaction when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Cladribine (Compound) ... |
DB00570 | DB11986 | 147 | 484 | [
"DDInter1936",
"DDInter648"
] | Vinblastine | Entrectinib | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
147,
24,
484
]
],
[
[
147,
24,
112
],
[
112,
23,
484
]
],
[
[
147,
23,
1539
],
[
1539,
24,
484
]
],
[
[
147,
24,
1072
],
[
1072,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Ofloxacin and Of... |
DB00106 | DB06402 | 618 | 1,079 | [
"DDInter4",
"DDInter1756"
] | Abarelix | Telavancin | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and sub... | Moderate | 1 | [
[
[
618,
24,
1079
]
],
[
[
618,
23,
112
],
[
112,
23,
1079
]
],
[
[
618,
24,
657
],
[
657,
63,
1079
]
],
[
[
618,
24,
543
],
[
543,
... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Telavancin
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor o... |
DB00603 | DB12267 | 303 | 1,476 | [
"DDInter1137",
"DDInter233"
] | Medroxyprogesterone acetate | Brigatinib | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Major | 2 | [
[
[
303,
25,
1476
]
],
[
[
303,
24,
629
],
[
629,
24,
1476
]
],
[
[
303,
63,
1184
],
[
1184,
24,
1476
]
],
[
[
303,
24,
1385
],
[
1385,
... | [
[
[
"Medroxyprogesterone acetate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimu... | Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when ... |
DB01591 | DB01619 | 667 | 830 | [
"DDInter1696",
"DDInter1441"
] | Solifenacin | Phenindamine | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Moderate | 1 | [
[
[
667,
24,
830
]
],
[
[
667,
63,
537
],
[
537,
40,
830
]
],
[
[
667,
63,
13
],
[
13,
24,
830
]
],
[
[
667,
63,
104
],
[
104,
1,
... | [
[
[
"Solifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Solifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[... | Solifenacin may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Solifenacin may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction ... |
DB00280 | DB09268 | 494 | 1,662 | [
"DDInter575",
"DDInter1464"
] | Disopyramide | Picosulfuric acid | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Major | 2 | [
[
[
494,
25,
1662
]
],
[
[
494,
25,
484
],
[
484,
63,
1662
]
],
[
[
494,
25,
1618
],
[
1618,
24,
1662
]
],
[
[
494,
24,
1573
],
[
1573,
... | [
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",... | Disopyramide may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Disopyramide may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may caus... |
DB00261 | DB03619 | 702 | 557 | [
"DDInter93",
"DDInter501"
] | Anagrelide | Deoxycholic acid | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that tissue. In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic... | Moderate | 1 | [
[
[
702,
24,
557
]
],
[
[
702,
24,
1479
],
[
1479,
24,
557
]
],
[
[
702,
25,
405
],
[
405,
63,
557
]
],
[
[
702,
25,
500
],
[
500,
2... | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deoxycholic acid"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"... | Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid
Anagrelide may lead to a major life threatening interaction when taken with Acalabruti... |
DB00321 | DB06282 | 21 | 516 | [
"DDInter78",
"DDInter1053"
] | Amitriptyline | Levocetirizine | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
21,
24,
516
]
],
[
[
21,
63,
701
],
[
701,
24,
516
]
],
[
[
21,
24,
1614
],
[
1614,
24,
516
]
],
[
[
21,
1,
358
],
[
358,
24,
... | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
]... | Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Nabilone an... |
DB01070 | DB09481 | 1,098 | 460 | [
"DDInter558",
"DDInter1113"
] | Dihydrotachysterol | Magnesium carbonate | A vitamin D that can be regarded as a reduction product of vitamin D2. | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Moderate | 1 | [
[
[
1098,
24,
460
]
],
[
[
1098,
63,
1252
],
[
1252,
23,
460
]
],
[
[
1098,
24,
853
],
[
853,
24,
460
]
],
[
[
1098,
64,
1041
],
[
1041,
... | [
[
[
"Dihydrotachysterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Dihydrotachysterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Di... | Dihydrotachysterol may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Dihydrotachysterol may cause a moderate interaction that could exacerbate diseases when taken with Magn... |
DB00023 | DB14444 | 305 | 151 | [
"DDInter127",
"DDInter924"
] | Asparaginase Escherichia coli | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
305,
24,
151
]
],
[
[
305,
24,
66
],
[
66,
24,
151
]
],
[
[
305,
25,
375
],
[
375,
24,
151
]
],
[
[
305,
64,
1057
],
[
1057,
24,... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cau... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Asparaginase Esche... |
DB00023 | DB00207 | 305 | 1,570 | [
"DDInter127",
"DDInter157"
] | Asparaginase Escherichia coli | Azithromycin | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 . It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually t... | Moderate | 1 | [
[
[
305,
24,
1570
]
],
[
[
305,
24,
1056
],
[
1056,
1,
1570
]
],
[
[
305,
24,
609
],
[
609,
63,
1570
]
],
[
[
305,
24,
912
],
[
912,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromycin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with ... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Telithromycin and Telithromycin (Compound) resembles Azithromycin (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clar... |
DB00640 | DB01142 | 1,585 | 1,264 | [
"DDInter31",
"DDInter593"
] | Adenosine | Doxepin | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
1585,
24,
1264
]
],
[
[
1585,
24,
401
],
[
401,
24,
1264
]
],
[
[
1585,
21,
28662
],
[
28662,
60,
1264
]
],
[
[
1585,
63,
600
],
[
600... | [
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Adenosine (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Doxepin (Compound)
Adenos... |
DB00761 | DB01100 | 1,621 | 1,568 | [
"DDInter1497",
"DDInter1470"
] | Potassium chloride | Pimozide | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium p... | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Major | 2 | [
[
[
1621,
25,
1568
]
],
[
[
1621,
21,
28766
],
[
28766,
60,
1568
]
],
[
[
1621,
64,
19
],
[
19,
24,
1568
]
],
[
[
1621,
25,
830
],
[
830,
... | [
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pimozide"
]
],
[
[
"Potassium chloride",
"{u} (Compound) causes {v} (Side Effect)",
"Hypotension"
],
[
"Hypotension",
"{u} (Side Effect) is c... | Potassium chloride (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Pimozide (Compound)
Potassium chloride may lead to a major life threatening interaction when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Pi... |
DB00512 | DB09268 | 91 | 1,662 | [
"DDInter1916",
"DDInter1464"
] | Vancomycin | Picosulfuric acid | Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatm... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
91,
24,
1662
]
],
[
[
91,
24,
1027
],
[
1027,
24,
1662
]
],
[
[
91,
63,
24
],
[
24,
24,
1662
]
],
[
[
91,
24,
1381
],
[
1381,
63... | [
[
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
],
... | Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin and Tol... |
DB00204 | DB14568 | 228 | 982 | [
"DDInter580",
"DDInter1000"
] | Dofetilide | Ivosidenib | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
228,
25,
982
]
],
[
[
228,
23,
112
],
[
112,
23,
982
]
],
[
[
228,
25,
608
],
[
608,
23,
982
]
],
[
[
228,
24,
976
],
[
976,
24,... | [
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Dofetilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Dofetilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Dofetilide may lead to a major life threatening interaction when taken with Lidocaine and Lidocaine may cause ... |
DB00872 | DB06228 | 1,080 | 792 | [
"DDInter438",
"DDInter1609"
] | Conivaptan | Rivaroxaban | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Major | 2 | [
[
[
1080,
25,
792
]
],
[
[
1080,
6,
8374
],
[
8374,
45,
792
]
],
[
[
1080,
21,
28703
],
[
28703,
60,
792
]
],
[
[
1080,
24,
466
],
[
466,
... | [
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Conivaptan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Rivaro... | Conivaptan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rivaroxaban (Compound)
Conivaptan (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Rivaroxaban (Compound)
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Da... |
DB00662 | DB14509 | 717 | 1,399 | [
"DDInter1873",
"DDInter1081"
] | Trimethobenzamide | Lithium carbonate | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
717,
24,
1399
]
],
[
[
717,
63,
506
],
[
506,
24,
1399
]
],
[
[
717,
24,
820
],
[
820,
24,
1399
]
],
[
[
717,
1,
1425
],
[
1425,
... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextro... | Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when... |
DB00377 | DB05812 | 1,494 | 1,374 | [
"DDInter1382",
"DDInter8"
] | Palonosetron | Abiraterone | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
1494,
24,
1374
]
],
[
[
1494,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
1494,
21,
29113
],
[
29113,
60,
1374
]
],
[
[
1494,
23,
112
],
[
... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Palonosetron",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compou... | Palonosetron (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Palonosetron (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Abiraterone (Compound)
Palonosetron may cause a minor interaction that can limit clinical effects when taken with Metroni... |
DB00762 | DB11932 | 613 | 327 | [
"DDInter973",
"DDInter3"
] | Irinotecan | Abametapir (topical) | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Abametapir is a member of bipyridines. | Moderate | 1 | [
[
[
613,
24,
327
]
],
[
[
613,
24,
124
],
[
124,
63,
327
]
],
[
[
613,
24,
292
],
[
292,
24,
327
]
],
[
[
613,
63,
79
],
[
79,
24,
... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Irinotecan m... |
DB00175 | DB01041 | 681 | 770 | [
"DDInter1509",
"DDInter1789"
] | Pravastatin | Thalidomide | Pravastatin is the 6-alpha-hydroxy acid form of [mevastatin]. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug. This drug was developed by Sankyo Co. Ltd.; however, the first approved pravasta... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
681,
24,
770
]
],
[
[
681,
25,
1668
],
[
1668,
1,
770
]
],
[
[
681,
6,
7524
],
[
7524,
45,
770
]
],
[
[
681,
21,
28784
],
[
28784,
... | [
[
[
"Pravastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Pravastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenalidomide"
],
[
"Lenal... | Pravastatin may lead to a major life threatening interaction when taken with Lenalidomide and Lenalidomide (Compound) resembles Thalidomide (Compound)
Pravastatin (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Thalidomide (Compound)
Pravastatin (Compound) causes Thrombocytopenia (Side Effect) and Thromboc... |
DB00087 | DB00877 | 599 | 629 | [
"DDInter41",
"DDInter1678"
] | Alemtuzumab | Sirolimus | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Moderate | 1 | [
[
[
599,
24,
629
]
],
[
[
599,
24,
1476
],
[
1476,
63,
629
]
],
[
[
599,
24,
167
],
[
167,
24,
629
]
],
[
[
599,
63,
1184
],
[
1184,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and H... |
DB01142 | DB09082 | 1,264 | 659 | [
"DDInter593",
"DDInter1934"
] | Doxepin | Vilanterol | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
1264,
24,
659
]
],
[
[
1264,
63,
1570
],
[
1570,
24,
659
]
],
[
[
1264,
24,
927
],
[
927,
63,
659
]
],
[
[
1264,
25,
1069
],
[
1069,
... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromycin"
],
[
... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encoraf... |
DB00539 | DB08899 | 11 | 129 | [
"DDInter1837",
"DDInter649"
] | Toremifene | Enzalutamide | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Major | 2 | [
[
[
11,
25,
129
]
],
[
[
11,
25,
918
],
[
918,
1,
129
]
],
[
[
11,
6,
8374
],
[
8374,
45,
129
]
],
[
[
11,
21,
28703
],
[
28703,
60,... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
... | Toremifene may lead to a major life threatening interaction when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Toremifene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Toremifene (Compound) causes Pruritus (Side Effect) and Pruritus (Side Ef... |
DB00439 | DB09065 | 289 | 760 | [
"DDInter341",
"DDInter424"
] | Cerivastatin | Cobicistat | On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Cana... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
289,
24,
760
]
],
[
[
289,
24,
1374
],
[
1374,
23,
760
]
],
[
[
289,
24,
723
],
[
723,
24,
760
]
],
[
[
289,
25,
609
],
[
609,
2... | [
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
... | Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Ap... |
DB00081 | DB11817 | 273 | 1,259 | [
"DDInter1838",
"DDInter165"
] | Tositumomab | Baricitinib | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
273,
25,
1259
]
],
[
[
273,
37,
1274
],
[
1274,
24,
1259
]
],
[
[
273,
25,
598
],
[
598,
24,
1259
]
],
[
[
273,
24,
949
],
[
949,
... | [
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening int... | Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Tositumomab may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Tositumomab ... |
DB00209 | DB01142 | 352 | 1,264 | [
"DDInter1886",
"DDInter593"
] | Trospium | Doxepin | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
352,
24,
1264
]
],
[
[
352,
24,
508
],
[
508,
24,
1264
]
],
[
[
352,
24,
1405
],
[
1405,
25,
1264
]
],
[
[
352,
6,
4304
],
[
4304,
... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Pro... | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenza... |
DB00795 | DB14115 | 50 | 1,312 | [
"DDInter1725",
"DDInter868"
] | Sulfasalazine | Human botulinum neurotoxin A/B immune globulin | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down i... | Infant botulism is a rare infectious disease occurring in infants in which _Clostridium botulinum_ colonize the large intestine and being to produce botulinum neurotoxin directly in the gut. As these neurotoxins interfere with cholinergic nervous transmission, patients initially present with evident of loss of muscle t... | Major | 2 | [
[
[
50,
25,
1312
]
],
[
[
50,
24,
123
],
[
123,
24,
1312
]
],
[
[
50,
24,
1132
],
[
1132,
25,
1312
]
],
[
[
50,
40,
712
],
[
712,
25... | [
[
[
"Sulfasalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Human botulinum neurotoxin A/B immune globulin"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"... | Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Human botulinum neurotoxin A/B immune globulin
Sulfasalazine may cause a moderate interaction that could exacerbate diseas... |
DB00341 | DB04844 | 1,242 | 843 | [
"DDInter343",
"DDInter1778"
] | Cetirizine | Tetrabenazine | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Moderate | 1 | [
[
[
1242,
24,
843
]
],
[
[
1242,
21,
28698
],
[
28698,
60,
843
]
],
[
[
1242,
24,
649
],
[
649,
24,
843
]
],
[
[
1242,
74,
701
],
[
701,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Cetirizine",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) is cau... | Cetirizine (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Tetrabenazine (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Tetrab... |
DB00495 | DB00687 | 139 | 870 | [
"DDInter1961",
"DDInter747"
] | Zidovudine | Fludrocortisone | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Moderate | 1 | [
[
[
139,
24,
870
]
],
[
[
139,
24,
1220
],
[
1220,
40,
870
]
],
[
[
139,
63,
251
],
[
251,
40,
870
]
],
[
[
139,
21,
28936
],
[
28936,
... | [
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Fludr... |
DB00970 | DB00978 | 0 | 739 | [
"DDInter466",
"DDInter1084"
] | Dactinomycin | Lomefloxacin | A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also d... | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Minor | 0 | [
[
[
0,
23,
739
]
],
[
[
0,
23,
945
],
[
945,
40,
739
]
],
[
[
0,
62,
1176
],
[
1176,
1,
739
]
],
[
[
0,
62,
1467
],
[
1467,
40,
... | [
[
[
"Dactinomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Dactinomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sparfloxacin"
],
... | Dactinomycin may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Dactinomycin may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Lomefloxacin... |
DB00108 | DB00688 | 1,066 | 955 | [
"DDInter1268",
"DDInter1251"
] | Natalizumab | Mycophenolate mofetil | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, ren... | Major | 2 | [
[
[
1066,
25,
955
]
],
[
[
1066,
25,
1096
],
[
1096,
40,
955
]
],
[
[
1066,
23,
1114
],
[
1114,
62,
955
]
],
[
[
1066,
64,
1184
],
[
1184,... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mycophenolate mofetil"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mycophenolic acid"
],
[
"Mycop... | Natalizumab may lead to a major life threatening interaction when taken with Mycophenolic acid and Mycophenolic acid (Compound) resembles Mycophenolate mofetil (Compound)
Natalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction... |
DB00434 | DB01215 | 13 | 1,418 | [
"DDInter459",
"DDInter677"
] | Cyproheptadine | Estazolam | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam. | Moderate | 1 | [
[
[
13,
24,
1418
]
],
[
[
13,
63,
523
],
[
523,
1,
1418
]
],
[
[
13,
24,
1216
],
[
1216,
40,
1418
]
],
[
[
13,
63,
905
],
[
905,
40,... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estazolam"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alprazolam"
],
... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam and Alprazolam (Compound) resembles Estazolam (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Estazolam (Comp... |
DB00363 | DB12332 | 695 | 1,619 | [
"DDInter419",
"DDInter1626"
] | Clozapine | Rucaparib | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Major | 2 | [
[
[
695,
25,
1619
]
],
[
[
695,
24,
222
],
[
222,
23,
1619
]
],
[
[
695,
23,
112
],
[
112,
23,
1619
]
],
[
[
695,
40,
87
],
[
87,
24... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine"... | Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Clozapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronid... |
DB12141 | DB12245 | 971 | 823 | [
"DDInter817",
"DDInter1863"
] | Gilteritinib | Triclabendazole | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
971,
24,
823
]
],
[
[
971,
62,
1247
],
[
1247,
23,
823
]
],
[
[
971,
63,
1612
],
[
1612,
24,
823
]
],
[
[
971,
64,
1622
],
[
1622,
... | [
[
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Gilteritinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
... | Gilteritinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Fost... |
DB00059 | DB09061 | 1,560 | 1,627 | [
"DDInter1404",
"DDInter284"
] | Pegaspargase | Cannabidiol | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Moderate | 1 | [
[
[
1560,
24,
1627
]
],
[
[
1560,
24,
609
],
[
609,
23,
1627
]
],
[
[
1560,
24,
888
],
[
888,
24,
1627
]
],
[
[
1560,
24,
1613
],
[
1613,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen ... |
DB00468 | DB08871 | 1,424 | 36 | [
"DDInter1557",
"DDInter666"
] | Quinine | Eribulin | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
1424,
24,
36
]
],
[
[
1424,
24,
122
],
[
122,
23,
36
]
],
[
[
1424,
23,
1247
],
[
1247,
23,
36
]
],
[
[
1424,
24,
519
],
[
519,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
],
[
"Vera... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Verapamil and Verapamil may cause a minor interaction that can limit clinical effects when taken with Eribulin
Quinine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazo... |
DB01611 | DB06402 | 1,487 | 1,079 | [
"DDInter893",
"DDInter1756"
] | Hydroxychloroquine | Telavancin | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and sub... | Major | 2 | [
[
[
1487,
25,
1079
]
],
[
[
1487,
21,
28680
],
[
28680,
60,
1079
]
],
[
[
1487,
63,
112
],
[
112,
23,
1079
]
],
[
[
1487,
24,
657
],
[
657... | [
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telavancin"
]
],
[
[
"Hydroxychloroquine",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v}... | Hydroxychloroquine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Telavancin (Compound)
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken wi... |
DB00443 | DB00681 | 251 | 1,287 | [
"DDInter195",
"DDInter85"
] | Betamethasone | Amphotericin B | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphot... | Moderate | 1 | [
[
[
251,
24,
1287
]
],
[
[
251,
21,
29876
],
[
29876,
60,
1287
]
],
[
[
251,
24,
1622
],
[
1622,
23,
1287
]
],
[
[
251,
63,
600
],
[
600,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
]
],
[
[
"Betamethasone",
"{u} (Compound) causes {v} (Side Effect)",
"Epilepsy"
],
[
"Epilepsy",
"{u} (Side Effect)... | Betamethasone (Compound) causes Epilepsy (Side Effect) and Epilepsy (Side Effect) is caused by Amphotericin B (Compound)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole and Voriconazole may cause a minor interaction that can limit clinical effects when taken wi... |
DB01064 | DB08907 | 1,148 | 1,344 | [
"DDInter987",
"DDInter280"
] | Isoprenaline | Canagliflozin | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
1148,
24,
1344
]
],
[
[
1148,
24,
549
],
[
549,
1,
1344
]
],
[
[
1148,
21,
28766
],
[
28766,
60,
1344
]
],
[
[
1148,
63,
739
],
[
739,... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Isoprenaline (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Canagliflozin (Compound)
Isoprenaline may cause a... |
DB00470 | DB00719 | 530 | 1,219 | [
"DDInter601",
"DDInter149"
] | Dronabinol | Azatadine | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Moderate | 1 | [
[
[
530,
24,
1219
]
],
[
[
530,
63,
13
],
[
13,
24,
1219
]
],
[
[
530,
24,
830
],
[
830,
1,
1219
]
],
[
[
530,
6,
8374
],
[
8374,
45... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine a... |
DB01001 | DB05294 | 688 | 1,069 | [
"DDInter1632",
"DDInter1917"
] | Salbutamol | Vandetanib | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Moderate | 1 | [
[
[
688,
24,
1069
]
],
[
[
688,
6,
8374
],
[
8374,
45,
1069
]
],
[
[
688,
21,
28719
],
[
28719,
60,
1069
]
],
[
[
688,
23,
1247
],
[
1247,... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
]
],
[
[
"Salbutamol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Salbutamol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vandetanib (Compound)
Salbutamol (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Vandetanib (Compound)
Salbutamol may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfametho... |
DB00651 | DB00975 | 746 | 1,317 | [
"DDInter613",
"DDInter573"
] | Dyphylline | Dipyridamole | Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis. | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Moderate | 1 | [
[
[
746,
24,
1317
]
],
[
[
746,
6,
17639
],
[
17639,
45,
1317
]
],
[
[
746,
21,
28956
],
[
28956,
60,
1317
]
],
[
[
746,
40,
1031
],
[
103... | [
[
[
"Dyphylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dipyridamole"
]
],
[
[
"Dyphylline",
"{u} (Compound) binds {v} (Gene)",
"PDE7B"
],
[
"PDE7B",
"{u} (Gene) is bound by {v} (Compound)",... | Dyphylline (Compound) binds PDE7B (Gene) and PDE7B (Gene) is bound by Dipyridamole (Compound)
Dyphylline (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Dipyridamole (Compound)
Dyphylline (Compound) resembles Theophylline (Compound) and Theophylline may cause a moderate interact... |
DB00307 | DB10989 | 1,101 | 496 | [
"DDInter202",
"DDInter858"
] | Bexarotene | Hepatitis A Vaccine | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Moderate | 1 | [
[
[
1101,
24,
496
]
],
[
[
1101,
24,
4
],
[
4,
24,
496
]
],
[
[
1101,
24,
738
],
[
738,
63,
496
]
],
[
[
1101,
23,
1419
],
[
1419,
2... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesu... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Bexarotene may cause a moderate interaction that could exacerbate disease... |
DB00586 | DB15093 | 1,512 | 1,654 | [
"DDInter537",
"DDInter1698"
] | Diclofenac | Somapacitan | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
1512,
24,
1654
]
],
[
[
1512,
63,
1645
],
[
1645,
24,
1654
]
],
[
[
1512,
24,
473
],
[
473,
24,
1654
]
],
[
[
1512,
25,
1468
],
[
1468... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
... | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repagl... |
DB00176 | DB06626 | 529 | 263 | [
"DDInter770",
"DDInter147"
] | Fluvoxamine | Axitinib | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Moderate | 1 | [
[
[
529,
24,
263
]
],
[
[
529,
24,
1215
],
[
1215,
23,
263
]
],
[
[
529,
24,
702
],
[
702,
24,
263
]
],
[
[
529,
24,
1593
],
[
1593,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
],
[
... | Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Axitinib
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anag... |
DB01001 | DB11837 | 688 | 1,297 | [
"DDInter1632",
"DDInter1351"
] | Salbutamol | Osilodrostat | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
688,
24,
1297
]
],
[
[
688,
62,
112
],
[
112,
23,
1297
]
],
[
[
688,
23,
1247
],
[
1247,
23,
1297
]
],
[
[
688,
24,
222
],
[
222,
... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Salbutamol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Salbutamol may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole an... |
DB01082 | DB06590 | 1,448 | 1,682 | [
"DDInter1713",
"DDInter329"
] | Streptomycin | Ceftaroline fosamil | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | Ceftaroline fosamil is a cephalosporin antibacterial indicated for the treatment of the following infections caused by designated susceptible bacteria: Acute bacterial skin and skin structure infections. Community-acquired bacterial pneumonia. | Moderate | 1 | [
[
[
1448,
24,
1682
]
],
[
[
1448,
63,
149
],
[
149,
40,
1682
]
],
[
[
1448,
63,
778
],
[
778,
1,
1682
]
],
[
[
1448,
24,
1453
],
[
1453,
... | [
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ceftaroline fosamil"
]
],
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ceftazidime"
... | Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Ceftazidime and Ceftazidime (Compound) resembles Ceftaroline fosamil (Compound)
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Cefixime and Cefixime (Compound) resembles Ceftaroline... |
DB00317 | DB05351 | 883 | 101 | [
"DDInter810",
"DDInter519"
] | Gefitinib | Dexlansoprazole | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Dexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of , which is composed of a racemic mixture of the R- and S-enantiomers. Compared to the older generatio... | Moderate | 1 | [
[
[
883,
24,
101
]
],
[
[
883,
40,
1069
],
[
1069,
23,
101
]
],
[
[
883,
24,
109
],
[
109,
23,
101
]
],
[
[
883,
24,
609
],
[
609,
2... | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound)",
"Vandetanib"
],
[
"Vandetanib",
"{u} may cause a mino... | Gefitinib (Compound) resembles Vandetanib (Compound) and Vandetanib may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a minor interaction that can lim... |
DB00529 | DB08881 | 789 | 868 | [
"DDInter779",
"DDInter1925"
] | Foscarnet | Vemurafenib | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
789,
25,
868
]
],
[
[
789,
21,
28847
],
[
28847,
60,
868
]
],
[
[
789,
23,
112
],
[
112,
23,
868
]
],
[
[
789,
24,
480
],
[
480,
... | [
[
[
"Foscarnet",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Foscarnet",
"{u} (Compound) causes {v} (Side Effect)",
"Eye disorder"
],
[
"Eye disorder",
"{u} (Side Effect) is caused by {v} ... | Foscarnet (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Foscarnet may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with ... |
DB00518 | DB04868 | 510 | 478 | [
"DDInter35",
"DDInter1293"
] | Albendazole | Nilotinib | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
510,
24,
478
]
],
[
[
510,
6,
4973
],
[
4973,
45,
478
]
],
[
[
510,
7,
14972
],
[
14972,
46,
478
]
],
[
[
510,
18,
2900
],
[
2900,
... | [
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Albendazole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Albendazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nilotinib (Compound)
Albendazole (Compound) upregulates C2CD2 (Gene) and C2CD2 (Gene) is upregulated by Nilotinib (Compound)
Albendazole (Compound) downregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Nilotinib (Compound)
Albendazole (Com... |
DB01097 | DB05679 | 1,377 | 1,683 | [
"DDInter1033",
"DDInter1907"
] | Leflunomide | Ustekinumab | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Major | 2 | [
[
[
1377,
25,
1683
]
],
[
[
1377,
62,
1461
],
[
1461,
23,
1683
]
],
[
[
1377,
23,
1193
],
[
1193,
62,
1683
]
],
[
[
1377,
25,
1042
],
[
10... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ustekinumab"
]
],
[
[
"Leflunomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E"... | Leflunomide may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Leflunomide may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gl... |
DB00717 | DB06372 | 1,197 | 259 | [
"DDInter1312",
"DDInter1594"
] | Norethisterone | Rilonacept | Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [no... | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Moderate | 1 | [
[
[
1197,
24,
259
]
],
[
[
1197,
24,
1619
],
[
1619,
63,
259
]
],
[
[
1197,
1,
1336
],
[
1336,
24,
259
]
],
[
[
1197,
24,
478
],
[
478,
... | [
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
... | Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Norethisterone (Compound) resembles Etonogestrel (Compound) and Etonogestrel may cause a moderate interaction ... |
DB00569 | DB08816 | 553 | 578 | [
"DDInter775",
"DDInter1802"
] | Fondaparinux | Ticagrelor | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in he... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Major | 2 | [
[
[
553,
25,
578
]
],
[
[
553,
21,
28646
],
[
28646,
60,
578
]
],
[
[
553,
23,
297
],
[
297,
62,
578
]
],
[
[
553,
64,
1578
],
[
1578,
... | [
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
]
],
[
[
"Fondaparinux",
"{u} (Compound) causes {v} (Side Effect)",
"Unspecified disorder of skin and subcutaneous tissue"
],
[
"Unspecified ... | Fondaparinux (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Fondaparinux may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause... |
DB01087 | DB06674 | 1,520 | 908 | [
"DDInter1520",
"DDInter837"
] | Primaquine | Golimumab | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
1520,
25,
908
]
],
[
[
1520,
25,
1487
],
[
1487,
24,
908
]
],
[
[
1520,
25,
1328
],
[
1328,
63,
908
]
],
[
[
1520,
62,
112
],
[
112,
... | [
[
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine... | Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Primaquine may lead to a major life threatening interaction when taken with Aurothioglucose and Aurothioglucose ... |
DB00363 | DB09054 | 695 | 384 | [
"DDInter419",
"DDInter905"
] | Clozapine | Idelalisib | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Major | 2 | [
[
[
695,
25,
384
]
],
[
[
695,
24,
222
],
[
222,
23,
384
]
],
[
[
695,
25,
1618
],
[
1618,
24,
384
]
],
[
[
695,
40,
1565
],
[
1565,
... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine... | Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Clozapine may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may caus... |
DB00081 | DB12364 | 273 | 1,421 | [
"DDInter1838",
"DDInter200"
] | Tositumomab | Betrixaban | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
273,
25,
1421
]
],
[
[
273,
23,
944
],
[
944,
62,
1421
]
],
[
[
273,
23,
539
],
[
539,
23,
1421
]
],
[
[
273,
24,
529
],
[
529,
... | [
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Tositumomab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",... | Tositumomab may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Betrixaban
Tositumomab may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may c... |
DB00443 | DB10343 | 251 | 962 | [
"DDInter195",
"DDInter160"
] | Betamethasone | Bacillus calmette-guerin substrain tice live antigen | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Major | 2 | [
[
[
251,
25,
962
]
],
[
[
251,
1,
617
],
[
617,
24,
962
]
],
[
[
251,
64,
1057
],
[
1057,
25,
962
]
],
[
[
251,
24,
270
],
[
270,
64... | [
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
],
[
"Budesonide... | Betamethasone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Bacillus calmette-guerin substrain tice live antigen
Betamethasone may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead t... |
DB01115 | DB06589 | 336 | 1,250 | [
"DDInter1291",
"DDInter1400"
] | Nifedipine | Pazopanib | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
336,
24,
1250
]
],
[
[
336,
6,
7950
],
[
7950,
45,
1250
]
],
[
[
336,
7,
8386
],
[
8386,
46,
1250
]
],
[
[
336,
18,
17513
],
[
17513,
... | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Nifedipine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
... | Nifedipine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pazopanib (Compound)
Nifedipine (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Pazopanib (Compound)
Nifedipine (Compound) downregulates SLC35A1 (Gene) and SLC35A1 (Gene) is downregulated by Pazopanib (Compound)
Nifedipine ... |
DB01118 | DB05679 | 33 | 1,683 | [
"DDInter76",
"DDInter1907"
] | Amiodarone | Ustekinumab | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
33,
24,
1683
]
],
[
[
33,
24,
1362
],
[
1362,
63,
1683
]
],
[
[
33,
63,
305
],
[
305,
24,
1683
]
],
[
[
33,
24,
309
],
[
309,
24... | [
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
... | Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia... |
DB10276 | DB11581 | 1,624 | 1,456 | [
"DDInter1623",
"DDInter1926"
] | Rotavirus vaccine | Venetoclax | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Major | 2 | [
[
[
1624,
25,
1456
]
],
[
[
1624,
64,
259
],
[
259,
24,
1456
]
],
[
[
1624,
25,
1476
],
[
1476,
63,
1456
]
],
[
[
1624,
25,
1093
],
[
1093... | [
[
[
"Rotavirus vaccine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Rotavirus vaccine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilonacept"
],
[
"Rilonacept"... | Rotavirus vaccine may lead to a major life threatening interaction when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Rotavirus vaccine may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a... |
DB00570 | DB01076 | 147 | 700 | [
"DDInter1936",
"DDInter133"
] | Vinblastine | Atorvastatin | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Moderate | 1 | [
[
[
147,
24,
700
]
],
[
[
147,
25,
1080
],
[
1080,
1,
700
]
],
[
[
147,
24,
788
],
[
788,
1,
700
]
],
[
[
147,
6,
12523
],
[
12523,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
],
[
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Conivaptan"
],
[
"Coniva... | Vinblastine may lead to a major life threatening interaction when taken with Conivaptan and Conivaptan (Compound) resembles Atorvastatin (Compound)
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin (Compound) resembles Atorvastatin (Compound)
Vinbl... |
DB00363 | DB01128 | 695 | 918 | [
"DDInter419",
"DDInter204"
] | Clozapine | Bicalutamide | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Major | 2 | [
[
[
695,
25,
918
]
],
[
[
695,
25,
129
],
[
129,
40,
918
]
],
[
[
695,
6,
8374
],
[
8374,
45,
918
]
],
[
[
695,
23,
112
],
[
112,
23... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bicalutamide"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{... | Clozapine may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide (Compound) resembles Bicalutamide (Compound)
Clozapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bicalutamide (Compound)
Clozapine may cause a minor interaction that can limit clinical effects whe... |
DB08899 | DB11995 | 129 | 1,634 | [
"DDInter649",
"DDInter143"
] | Enzalutamide | Avatrombopag | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Avatrombopag (_Doptelet_), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation,[A33097,L2824] thereby decreasing the need for blood transfusions. Patients with thrombocytopenia and chronic liver disease often require pla... | Major | 2 | [
[
[
129,
25,
1634
]
],
[
[
129,
63,
1622
],
[
1622,
24,
1634
]
],
[
[
129,
25,
760
],
[
760,
24,
1634
]
],
[
[
129,
64,
74
],
[
74,
... | [
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avatrombopag"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voriconazole"
],
[
"Vo... | Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole and Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Enzalutamide may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat ... |
DB00586 | DB00960 | 1,512 | 887 | [
"DDInter537",
"DDInter1471"
] | Diclofenac | Pindolol | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Moderate | 1 | [
[
[
1512,
24,
887
]
],
[
[
1512,
24,
819
],
[
819,
40,
887
]
],
[
[
1512,
63,
88
],
[
88,
40,
887
]
],
[
[
1512,
24,
1121
],
[
1121,
... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
],
[
... | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol (Compound) resembles Pindolol (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol (Compound) resembles Pindolol (Compound)
Dicl... |
DB00390 | DB01233 | 1,252 | 1,311 | [
"DDInter554",
"DDInter1197"
] | Digoxin | Metoclopramide | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Minor | 0 | [
[
[
1252,
23,
1311
]
],
[
[
1252,
24,
1151
],
[
1151,
40,
1311
]
],
[
[
1252,
21,
28714
],
[
28714,
60,
1311
]
],
[
[
1252,
24,
1620
],
[
... | [
[
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metoclopramide"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
],
[
"... | Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib (Compound) resembles Metoclopramide (Compound)
Digoxin (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Metoclopramide (Compound)
Digoxin may cause a moderate interaction that ... |
DB06692 | DB13151 | 930 | 1,380 | [
"DDInter113",
"DDInter101"
] | Aprotinin | Anti-inhibitor coagulant complex | Aprotinin is a protein-based drug that is also known as bovine pancreatic trypsin inhibitor (BPTI). Since it demonstrates the capacity to slow fibrinolysis, it has been employed to reduce bleeding during complex surgery such as heart and liver surgery. For this use, it is typically administered by injection. The goal o... | Anti-inhibitor coagulant complex, also known as FEIBA (factor eight inhibitor bypassing activity), contains several proteins involved in the prothrombinase complex. It is used to control bleeding in hemophilia A and B patients with inhibitors. | Major | 2 | [
[
[
930,
25,
1380
]
],
[
[
930,
63,
20
],
[
20,
24,
335
],
[
335,
25,
1380
]
],
[
[
930,
25,
979
],
[
979,
64,
335
],
[
335,
25,
1... | [
[
[
"Aprotinin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anti-inhibitor coagulant complex"
]
],
[
[
"Aprotinin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tenecteplase"
],
... | Aprotinin may cause a moderate interaction that could exacerbate diseases when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Tranexamic acid and Tranexamic acid may lead to a major life threatening interaction when taken with Anti-inhibitor coag... |
DB08826 | DB08885 | 1,292 | 363 | [
"DDInter489",
"DDInter33"
] | Deferiprone | Aflibercept | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Dalt... | Major | 2 | [
[
[
1292,
25,
363
]
],
[
[
1292,
25,
384
],
[
384,
63,
363
]
],
[
[
1292,
64,
139
],
[
139,
24,
363
]
],
[
[
1292,
64,
1057
],
[
1057,
... | [
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aflibercept"
]
],
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u... | Deferiprone may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Aflibercept
Deferiprone may lead to a major life threatening interaction when taken with Zidovudine and Zidovudine may cause a moderate i... |
DB00738 | DB05351 | 485 | 101 | [
"DDInter1420",
"DDInter519"
] | Pentamidine | Dexlansoprazole | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Dexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of , which is composed of a racemic mixture of the R- and S-enantiomers. Compared to the older generatio... | Moderate | 1 | [
[
[
485,
24,
101
]
],
[
[
485,
25,
1069
],
[
1069,
23,
101
]
],
[
[
485,
24,
609
],
[
609,
24,
101
]
],
[
[
485,
24,
1381
],
[
1381,
... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Van... | Pentamidine may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromyc... |
DB01592 | DB12035 | 1,596 | 943 | [
"DDInter975",
"DDInter1641"
] | Iron | Sarecycline | A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletio... | Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe... | Moderate | 1 | [
[
[
1596,
24,
943
]
],
[
[
1596,
24,
1606
],
[
1606,
24,
943
]
],
[
[
1596,
63,
1283
],
[
1283,
24,
943
]
],
[
[
1596,
23,
1193
],
[
1193,... | [
[
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
],
[
... | Iron may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate and Lanthanum carbonate may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Iron may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxid... |
DB00250 | DB01259 | 10 | 392 | [
"DDInter475",
"DDInter1024"
] | Dapsone | Lapatinib | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
10,
24,
392
]
],
[
[
10,
6,
8374
],
[
8374,
45,
392
]
],
[
[
10,
21,
28645
],
[
28645,
60,
392
]
],
[
[
10,
24,
112
],
[
112,
23... | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Dapsone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Dapsone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lapatinib (Compound)
Dapsone (Compound) causes Cough (Side Effect) and Cough (Side Effect) is caused by Lapatinib (Compound)
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may ca... |
DB00342 | DB09330 | 1,181 | 985 | [
"DDInter1770",
"DDInter1352"
] | Terfenadine | Osimertinib | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
1181,
24,
985
]
],
[
[
1181,
23,
1247
],
[
1247,
23,
985
]
],
[
[
1181,
24,
1478
],
[
1478,
24,
985
]
],
[
[
1181,
24,
657
],
[
657,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Terfenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Terfenadine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.